Novo Nordisk A/S (NYSE:NVO) Trading Up 3.6% – Time to Buy?

Shares of Novo Nordisk A/S (NYSE:NVO) shot up 3.6% on Monday . The stock traded as high as $51.09 and last traded at $49.35. 29,985,905 shares traded hands during trading, an increase of 11% from the average session volume of 26,940,416 shares. The stock had previously closed at $47.64.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo forced a retreat by telehealth firm Hims & Hers: Hims pulled its $49 compounded semaglutide offering after legal threats and regulatory scrutiny, removing a near‑term, self‑pay price competitor to Wegovy. Article Title
• Positive Sentiment: Novo escalated with a patent‑infringement lawsuit vs Hims seeking to block compounded semaglutide sales — a legal step that should strengthen Novo’s intellectual‑property moat in the short to medium term. Article Title
• Positive Sentiment: Market reaction: Hims & Hers shares plunged on the regulatory/legal pushback, while Novo shares have bounced as investors view the threat to Wegovy/Ozempic economics as reduced. Article Title
• Positive Sentiment: Novo launched a share repurchase programme (part of a DKK 15bn plan) — a capital‑allocation move investors often view as supportive of the stock and EPS. Article Title
• Neutral Sentiment: Company & media pushback: Hims framed Novo’s lawsuit as aggressive PR; this dispute could draw out in court and media, creating short‑term volatility but an unclear long‑term impact. Article Title
• Negative Sentiment: Guidance shock: Novo sharply cut 2026 revenue and profit guidance, citing steep U.S. price declines and competition; the guidance revision triggered a prior ~25% one‑day drop and remains a key downside risk for near‑term earnings and valuation. Article Title
• Negative Sentiment: Regulatory headwind for Novo itself: The FDA sent a letter saying a Novo TV ad for the Wegovy pill contained “false or misleading” claims and requested corrective action — this raises reputational and marketing risks and could constrain U.S. promotional activity. Article Title

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday. CICC Research began coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective on the stock. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Morgan Stanley reaffirmed an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Finally, Citigroup assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. Seven equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Stock Up 3.6%

The business’s 50 day moving average is $53.61 and its 200-day moving average is $53.73. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company has a market cap of $220.35 billion, a PE ratio of 14.22 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.63%.

Hedge Funds Weigh In On Novo Nordisk A/S

Hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its stake in Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares in the last quarter. Capital International Investors boosted its position in shares of Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the period. Boston Partners purchased a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $310,199,000. SG Americas Securities LLC grew its stake in Novo Nordisk A/S by 2,101.5% during the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after buying an additional 2,274,925 shares during the last quarter. Finally, Bank of Montreal Can increased its position in Novo Nordisk A/S by 101.4% during the second quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock worth $170,845,000 after buying an additional 1,246,467 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.